---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-050338"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T12:26:04.252501+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences raises $2.5M via registered direct offering and private placement at $3.07/unit

## Summary
- Entered into securities purchase agreement with institutional investor for 800,695 shares/pre-funded warrants at $3.07/unit, raising ~$2.5M gross.
- Concurrent private placement of warrants to purchase 800,695 shares at $3.07, exercisable immediately, expire in 5.5 years.
- Amended existing warrants for 164,656 shares from $15.00 to $3.07 exercise price effective upon closing.
- Placement agent Maxim Group receives 7% cash fee and 40,035 warrants at $3.38 exercise price.
- Offering expected to close on or about April 24, 2023.

## SEC filing metadata
- accession: 0001104659-23-050338
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465923050338/0001104659-23-050338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465923050338/tm2313709d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-050338
- JSON: https://secwatch.observer/filing/0001104659-23-050338.json
- Plain text: https://secwatch.observer/filing/0001104659-23-050338.txt

## Key facts
- Material Agreements
  Vyome Holdings, Inc entered into Securities Purchase Agreement with a certain institutional investor valued at approximately $2.46 million (effective 2023-04-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a certain institutional investor
  - Value: approximately $2.46 million
  - Effective: 2023-04-20
  source text: On April 20, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 291,395 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) pre-funded warrants to purchase an aggregate of 509,300 shares of Common Stock (the “Pre-funded Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000110465923050338/0001104659-23-050338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.